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INTRODUCTION
Beta-hemolytic streptococcal isolates from humans can be
subdivided into large-colony and small-colony (<0.5 mm in
diameter) formers (1). The small colony-forming  -hemoly-
tic strains with Lancefield group A, C, F, or G antigens belong
to the anginosus or previously termed ‘Streptococcus milleri’
species group. Members of the anginosus group (Streptococcus
anginosus, Streptococcus constellatus, and Streptococcus intermedius)
are considered part of the viridans group streptococci (VGS),
the majority of which display  -hemolytic or non-hemolytic
reactions. The VGS also include Streptococcus mitis, Streptococ-
cus oralis, Streptococcus mutans, Streptococcus salivarius, Streptococ-
cus sanguis, and Streptococcus bovis (1-3). Although small-colony-
forming  -hemolytic VGS are found as commensals whose
pathogenic abilities appear to be much more subtle than those
of the pyogenic streptococci, they may also participate in vari-
ous infections such as subacute bacterial endocarditis, catheter-
related and neutropenia-related bloodstream infections, puru-
lent abdominal, hepatobiliary, brain, and dental infections
(3-5). In addition, they play a significant role as a reservoir
of antimicrobial resistance genes, transferring different resis-
tance traits to more pathogenic organisms such as Streptococ-
cus pneumoniae and Streptococcus pyogenes (6).
Beta-lactam agents are the treatment of choice for VGS
infections, but increasing resistance to penicillin has recent-
ly been reported in many parts of the world (7). Macrolides
and related drugs have been suggested as alternatives, but
recent studies have shown that macrolide resistance may also
be a problem (7). Moreover, Clinical and Laboratory Standards
Institute (CLSI) recommended that VGS isolated from nor-
mally sterile body sites should be tested for penicillin suscep-
tibility using the minimum inhibitory concentration (MIC)
method, and interpretive criteria for the VGS should be used
(2). However, laboratory personnel have difficulty in differ-
entiating  -hemolytic VGS from pyogenic streptococci based
on colony size. Although many recent studies have elucidated
susceptibilities of VGS isolated from clinical samples (main-
ly from blood cultures) to various anti- microbial agents, such
studies on  -hemolytic VGS from the various specimens are
scarce.
The objectives of the present study were to determine the
incidence and patterns of antimicrobial resistance among  -
hemolytic VGS isolated from various clinical specimens in a
Korean hospital and to clarify the macrolide resistance phe-
notypes and genotypes of erythromycin-resistant isolates. 
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Antimicrobial Susceptibility Patterns and Macrolide Resistance Genes
of  -Hemolytic Viridans Group Streptococci in a Tertiary Korean 
Hospital
The aim of this study was to investigate antimicrobial susceptibilities and macrolide
resistance mechanisms of  -hemolytic viridans group streptococci (VGS) in a ter-
tiary Korean hospital. Minimum inhibitory concentrations (MICs) of seven antimi-
crobials were determined for 103  -hemolytic VGS isolated from various speci-
mens. The macrolide resistance mechanisms of erythromycin-resistant isolates
were studied by the double disk test and polymerase chain reaction (PCR). The
overall resistance rates of  -hemolytic VGS were found to be 47.5% to tetracy-
cline, 3.9% to chloramphenicol, 9.7% to erythromycin, and 6.8% to clindamycin,
whereas all isolates were susceptible to penicillin G, ceftriaxone, and vancomycin.
Among ten erythromycin-resistant isolates, six isolates expressed a constitutive
MLSB (cMLSB) phenotype, and each of the two isolates expressed the M pheno-
type, and the inducible MLSB (iMLSB) phenotype. The resistance rates to erythro-
mycin and clindamycin of  -hemolytic VGS seemed to be lower than those of
non- -hemolytic VGS in our hospital, although cMLSB phenotype carrying erm(B)
was dominant in  -hemolytic VGS. 
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MATERIALS AND METHODS
One hundred and three isolates of  -hemolytic VGS isolated
from various clinical specimens were collected between Jan-
uary 2003 and December 2004 at Wonju Christian Hospital
in South Korea. Isolates were identified by standard methods:
Streptex latex agglutination assay (Murex Biotech Limited,
Dartford, England) and the API Rapid ID32 STREP system
(bioMerieux, Marcy-l’Etoile, France). These were stored in
thioglycollate broth plus 20% glycerol at -70℃until studied.
Susceptibility to penicillin G, erythromycin, clindamycin,
ceftriaxone, chloramphenicol, tetracycline (Sigma Chemical
Co, St. Louis, MO, U.S.A.), and vancomycin (Daewoong Lilly,
Korea) was determined by an agar dilution method (2), and
MICs were interpreted using the CLSI criteria (2). Macrolide
resistance phenotypes of erythromycin-resistant isolates were
determined using a double-disk test with erythromycin (15
g) and clindamycin (2  g) disks on Mueller-Hinton agar
plates containing 5% sheep blood. Genomic DNA was
extracted with an Easy-DNA kit (Invitrogen, Carlsbad, CA,
U.S.A.), according to the manufacturer’s instructions. The
presence of erm and mef class genes was determined by PCR
amplification using previously described primers specific for
erm(A), erm(B), erm(C), erm(TR), and erm(A) (8). To confirm
that PCR reactions were amplifying the target sequences for
specific primers, PCR products were sequenced (Macrogen
Inc., Seoul, Korea). 
RESULTS
Of the 103  -hemolytic VGS, nine (8.7%), forty (38.8%),
and fifty-three (51.5%) isolates were agglutinated with group
C, F, and G antisera, respectively. One isolate of  -hemolytic
S. intermedius was nongroupable. Using the agar dilution
method, the overall resistance (intermediate and resistance)
rates of  -hemolytic VGS were measured at 47.5% to tetra-
cycline, 3.9% to chloramphenicol, 9.7% to erythromycin
and 6.8% to clindamycin, whereas all isolates were suscepti-
ble to penicillin G, ceftriaxone, and vancomycin. One S.
intermedius isolated from peritoneal fluid was susceptible to
tetracycline, erythromycin, and clindamycin. Resistance
rates to tetracycline, erythromycin, and clindamycin of group
F and G isolates were 37.5% vs. 52.8%, 17.5% vs. 5.7%,
and 15.0% vs. 3.8%, respectively. All of group C  -hemolyt-
ic VGS isolates were susceptible to erythromycin, clindamy-
cin, and chloramphenicol, although tetracycline resistance
rate (66.7%) of group C was higher than other serogroups
(Table 1). 
Among the  -hemolytic VGS, 68 (66.0%) and 25 (24.3%)
were identified as S. anginosus and S. constellatus, respectively.
The remaining isolates included Gemella haemolysans (six
isolates), S. intermedius (one isolate), S. oralis (one isolate), S.
salivarius (one isolate), and Streptococcus alactolyticus (one iso-
late). The serogroup proportions of S. anginosus were G (63.2











(No. of isolates tested)
C (9) 0 0 66.7 0
F (40) 17.5 15.0 37.5 5.0
G (53) 5.7 3.8 52.8 3.8
Total* (103) 9.7 6.8 47.5 3.9




No. of isolates by specimen type (No. of erythromycin-resistant isolates)
Blood
Sero-
group BW Sputum Throat Urine Cervix Wound Others
‖
Total
S. anginosus (68) C 0 0 0 1 1 0 0 0 2
F 2 0 3 (1*) 0 8 (3
� ) 4 (1
� ) 3 (1
�)3 2 3
G 0 5 (1*) 19 (1*) 0 0 0 16 (1
�)3 4 3
S. constellatus (25) C 0 2 0 2 0 0 1 0 5
F0 2 40 1 04 0 1 1
G05 200 0 2 0 9
S. intermedius (1) NG 0 0 0 0 0 0 0 1 1
Gemella haemolysans (6) C 0 0 0 0 0 0 1 0 1
F 1 1 1 0 0 0 2 (1*) 0 5
S. oralis 2 (1) C 0 0 1 0 0 0 0 0 1
S. salivarius (1) F 0 0 0 0 1 0 0 0 1
S. alactolyticus (1) G 0 0 1 0 0 0 0 0 1
Total 3 15 31 3 11 4 29 7 103
Table 2. Distribution of erythromycin-resistant  -hemolytic viridans group streptococci according to specimen type and serogroup
*cMLSB phenotype with erm(B) gene; 
�
cMLSB phenotype with erm(B) gene (1), iMLSB phenotype with erm(TR) gene (1), and iMLSB phenotype with
erm(B) gene (1); 
�
cMLSB phenotype with erm(B) and erm(TR) gene; 
�
M phenotype with mef(A) gene; 
‖Peritoneal fluid (1), suction tip (3), bile (1), gall
bladder (1), gastric washing (1). BW, bronchial washing; NG, nongroupable.those of S. constellatus were F (44.0%), G (36.0%), and C (20.0
%). Among the S. anginosus isolates, group G was frequently
isolated from the lower respiratory tract specimens such as
bronchial washing and sputum (55.8%), and wound cultures
(37.2%), whereas group F was somewhat prevalent in geni-
tourinary tract specimens (52.2%). As contrasted with S. angi-
nosus, the specimen distribution of S. constellatus by serogroups
had little or no difference. Of the nine erythromycin-resistant
S. anginosus strains, six and three were group F and G, respec-
tively. Among ten erythromycin-resistant isolates, six isolates
expressed a constitutive MLSB (cMLSB) phenotype, and each
of the two isolates expressed an M phenotype and an inducible
MLSB (iMLSB) phenotype, respectively. All cMLSB and M phe-
notypes carried the erm(B) and mef(A) genes, respectively. Of
the two iMLSB phenotypes, each one carried erm(B) and erm
(TR) gene, respectively. One isolate with the cMLSB pheno-
type carried both of erm(B) and erm(TR) genes (Table 2).
DISCUSSION
Although most strains of S. anginosus group have been
known to be non-hemolytic or  -hemolytic, it is estimated
that 25% are  -hemolytic (9). Lawrence et al. (10) reported
that a majority (84%) of the S. milleri strains possessed Lance-
field group antigen (3 A, 27 C, 41 F, and 5 G), whereas 16%
were nongroupable. In this study, however, group G was the
most commonly isolated serogroup among  hemolytic VGS,
and only one strain was nongroupable. Many authors (1, 3)
have reported that: S. anginosus strains may possess Lance-
field group A, C, F, or G antigens; S. constellatus strains are
more -hemolytic  than S. anginosus or S. intermedius, and pos-
sess mainly Lancefield group F antigens; and that isolates of
S. intermedius strains are rarely  -hemolytic. Some authors
(1, 5) have documented that there tends to be an association
between the clinical specimen sources and three species of
anginosus group organisms. In addition,  -hemolytic group
C strains of S. constellatus constitute two subspecies: S. constel-
latus subsp. constellatus, which is isolated from a relatively
broad clinical background, and S. constellatus subsp. pharyn-
gis, which shows a close association with the human throat
and pharyngitis. S. anginosus isolates are commonly isolated
from urogenital and gastrointestinal sources, and strains of
S. constellatus have been isolated relatively frequently from the
respiratory tract and many other sources, while S. intermedius
strains are often isolated among the polymicrobial flora of
deep-seated abscesses, notably in the liver and brain. Our
results are also consistent with above findings.
Identification to the species level among  -hemolytic VGS
should not be ignored because  -hemolytic VGS differ from
large-colony-forming  -hemolytic streptococci in clinical
significance and interpretive criteria of susceptibility. Addi-
tionally, anginosus group organisms recovered from abscess
or wound specimens, even when other organisms are present,
are likely to be pathogens rather than contaminants. Careful
evaluation of the significance of  -hemolytic VGS according
to specimen types is needed, and a clinical laboratory setting
for the precise identification of  -hemolytic VGS should be
a priority.
Until the 1980s, VGS were considered uniformly suscep-
tible to  -lactam antibiotics, but resistance had spread rapid-
ly in the 1990s. VGS that are not susceptible to penicillin
also showed reduced susceptibility to ceftriaxone, erythro-
mycin, and clindamycin. The resistance rates to penicillin,
clindamycin, erythromycin, and ceftriaxone of VGS isolated
from blood cultures in our previous study (8) were 57.6%,
33.9%, 17.9%, and 9%, respectively. In this study, howev-
er, any of  -hemolytic VGS isolates did not show resistance to
either penicillin or to ceftriaxone. In our previous study, the
overall resistance rates of  -hemolytic streptococci were found
to be 80.0% to tetracycline, 22.8% to chloramphenicol, 20.2
% to erythromycin and 19.1% to clindamycin, whereas all
isolates were susceptible to penicillin G, ceftriaxone and van-
comycin (11). These results suggested that susceptibilities of
-hemolytic VGS to  -lactams are similar to pyogenic  -
hemolytic streptococci rather than non- -hemolytic VGS.
The rate of clindamycin resistance in VGS has been deter-
mined mainly by the distribution of MLSB resistance phe-
notypes. In this study, all of erythromycin-susceptible iso-
lates were susceptible to clindamycin, and the cMLSB phe-
notype was the most frequently observed mechanism among
erythromycin-resistant isolates. The proportion of the M phe-
notype and iMLSB was equal. However, the numbers of ery-
thromycin-resistant strains were too small to draw a conclu-
sion. As for the non- -hemolytic VGS, the distribution of
MLSB phenotypes of  -hemolytic VGS may also vary with
many factors such as geography, specimen sources, species
identified, and so on (8, 12). 
We think that susceptibility testing of  -lactams for treat-
ment of  -hemolytic VGS is not necessary for clinical pur-
pose, and may not be done routinely in the hospitals, because,
as with vancomycin, resistant strains have not been detected
in this study. The resistance rates to erythromycin and clin-
damycin of  -hemolytic VGS seemed to be relatively lower
than non- -hemolytic VGS in our hospital, although cMLSB
phenotype-carrying erm(B) was dominant in  -hemolytic
VGS. Further epidemiologic studies are needed to confirm
whether or not our susceptibility data on  -hemolytic VGS
are restricted to our area. 
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